Adherence to highly active antiretroviral therapy

Southern African Journal of HIV Medicine

Volumn , Issue 7, 2002, Pages 35-42

  Friedland, Gerald ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG RESEARCH; HEALTH BEHAVIOR; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MEDICAL INFORMATION; MOTIVATION; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; SIDE EFFECT; SOUTH AFRICA; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0036093993     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. The era of adherence to HIV therapy
4. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
5. Attaining higher goals in HIV treatment: The central importance of adherence
6. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
7. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
8. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
9. Three-year durability of response with an efavirenz (EFV) containing regimen: 144 week follow-up from study 006
10. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
11. Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy
12. Clinical, immunological and virological effectiveness of antiretroviral therapy in a resource-poor setting: The Senegalese experience
13. Evaluation at 6 months of a once-a-day-HAART regimen in treatment-naïve HIV-1-infected adults in Senegal (ANRS 12-04 Study)
14. Prospective trial of CBV+IDV in West Africa
15. Initial data on antiretroviral adherence in Cape Town, South Africa
16. Adherence to antiretroviral therapy-achievable in the South African context?
17. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
18. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
19. Antiretroviral adherence and its consistency predict biologic outcomes in HIV clinical trials
20. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
21. Adherence in patients treated with HAART: Influence in hospital admissions
22. Further characterizing determinants of disease progression among HIV-1 infected patients initiating triple drug therapy
23. Public health implications of antiretroviral therapy and HIV drug resistance
24. Reduced antirectroviral drug susceptibility among patients with primary HIV infection
25. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
26. Correlates of risky behaviors among young and older men having sexual relations with men in Montreal, Quebec, Canada
27. Behavioural and biologic evidence of persistent high-risk behaviour in an HIV primary care population
28. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
29. A comparison study of multiple measures of adherence to HIV protease inhibitors
30. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments
31. Patient-reported nonadherence to HAART is related to protease inhibitor levels
32. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications
33. Adherence in AIDS clinical trials: A framework for clinical research and clinical care
34. Stages and processes of self-change of smoking: Toward an integrative model of change
35. Changing AIDS-risk behaviour
36. A method for assessing patient readiness to begin and adhere to highly active antiretroviral therapy (HAART)
37. Trust and the acceptance of and adherence to antiretroviral therapy
38. Intravenous drug use, relationship with providers and stage of HIV disease influence the prescription rate of protease inhibitors
39. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients
40. Effectiveness of interventions to improve patients compliance-a meta analysis
41. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
42. High-compliance tuberculosis treatment programme in a rural community (Public Health)
43. Impact of directly observed therapy on outcomes in HIV clinical trials